Africa: Aids 2026 - Some Pieces Falling Into Place for Monthly HIV Prevention Pill, but Key Data Not Yet In
5 Articles
5 Articles
Africa: Aids 2026 - Some Pieces Falling Into Place for Monthly HIV Prevention Pill, but Key Data Not Yet in
If an HIV prevention pill that provides a month of protection at a time performs well in two ongoing clinical trials, it could become the next big thing in HIV prevention after the lenacapavir injection. A new licensing agreement is paving the way for South Africa's Aspen Pharmacare to produce the pill should the study findings be positive and the drug be registered.
Anvisa approves lenacapavir injection for HIV prevention For a healthy young woman in South Africa, the higher risk of contracting HIV may come precisely from someone she would like to trust, but she can't. Maybe she doesn't know, for example, the partner's serological situation, can't always insist on using condoms or have little control over the possibility of maintaining other relationships. For this, there is one option: Pre-Exposition Proph…
Can a Cheap Pill Finally End the HIV Epidemic?
Imagine a world where keeping HIV at bay is as simple as a single monthly pill. And the best part? It’s affordable for everyone, everywhere. Thanks to a groundbreaking partnership between pharmaceutical giant Merck and independent, generic manufacturers, that future is inching closer to reality. They are set to mass-produce a budget-friendly version of its innovative long-acting prevention medication. By opening the doors to wider production…
Rio de Janeiro – HIV pre-exposure prophylaxis (PrEP) with the capsid inhibitor lenacavir has proven highly effective in the open-label phases of the pivotal Purpose 1 and 2 studies. According to data presented at the AIDS 2026 conference in Rio de Janeiro, among the nearly 7,000 participants, only one case of HIV infection occurred during the one-year study period...
The 26th International AIDS Conference opened this Monday in Rio de Janeiro, amidst a paradox. On the one hand, science is revolutionizing HIV prevention, with medications offering a level of protection against the virus similar to that of a vaccine. On the other hand, activists point to the unequal distribution of these medications.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
